Metabolic dysfunction-associated steatotic liver disease is entering a new therapeutic era. The transition from NAFLD to MASLD has aligned disease definition around the pathophysiology of cardiometabolic risk factors and accelerated drug development. Emerging pharmacological strategies targeting lipid metabolism, inflammation and fibrosis are transforming management. This Collection highlights advances that collectively signal a turning point in metabolic liver disease.
Gautheron et al. (Tue,) studied this question.